US Diagnostic Market Outlook 2020
Diagnostic products and services in the US have been witnessing a steady demand over the past few years, backed by an increase in the insured population under Public Protection and Affordable Care Act, increasing awareness about early disease detection, increasing chronic diseases and an ever increasing aging population.
The US diagnostic market accounts for a major portion of the country’s total healthcare market. The market growth is expected to grow in the coming years mainly due to segments, such as oncology, molecular diagnostics, point-of-care testing, personalized medicine and the associated companion diagnostics.
According to our research report, “US Diagnostic Market Outlook 2020”, the US represents the world’s largest and most matured diagnostic markets. Despite economic challenges and changes in the market environment in the wake of Patient Protection and Affordable Care Act, the US Diagnostics market has experienced a steady growth over the past few years. Looking ahead, the US market for diagnostic products is expected to slow down as the emerging markets offer a more lucrative business opportunity to the industry players. However, the US is expected to maintain its leading position as the world's largest IVD products market, growing at a moderate CAGR of 6.3% during 2014-2020.
Our segment-level analysis showed that the immunoassay market accounted for the largest market share of the total IVD products market. Although the segment is expected to witness a slow growth in the future due to competition from alternative technologies, especially molecular diagnostics, it is likely to sustain its topmost position in the market by 2020. Considering the growth rates, the market for molecular diagnostic IVD products is anticipated to outpace all the other segments, owing to selectivity, sensitivity, speed, accuracy, cost-effectiveness and breadth of application advantages over alternative IVDs.
Our report has been authored to evaluate the US diagnostic market potentials, and identify future growth opportunities. It provides extensive research and analysis on current market trends and future forecasts on all prominent diagnostic techniques including medical imaging and in vitro diagnostics.
The report also provides an insight into the market consolidation over the past few years, the competitive landscape of both the diagnostics and lab services market. The future analysis of the market scenario is likely to assist the intending clients to take informed and proactive business decisions in the evolving US diagnostic market.
The US diagnostic market accounts for a major portion of the country’s total healthcare market. The market growth is expected to grow in the coming years mainly due to segments, such as oncology, molecular diagnostics, point-of-care testing, personalized medicine and the associated companion diagnostics.
According to our research report, “US Diagnostic Market Outlook 2020”, the US represents the world’s largest and most matured diagnostic markets. Despite economic challenges and changes in the market environment in the wake of Patient Protection and Affordable Care Act, the US Diagnostics market has experienced a steady growth over the past few years. Looking ahead, the US market for diagnostic products is expected to slow down as the emerging markets offer a more lucrative business opportunity to the industry players. However, the US is expected to maintain its leading position as the world's largest IVD products market, growing at a moderate CAGR of 6.3% during 2014-2020.
Our segment-level analysis showed that the immunoassay market accounted for the largest market share of the total IVD products market. Although the segment is expected to witness a slow growth in the future due to competition from alternative technologies, especially molecular diagnostics, it is likely to sustain its topmost position in the market by 2020. Considering the growth rates, the market for molecular diagnostic IVD products is anticipated to outpace all the other segments, owing to selectivity, sensitivity, speed, accuracy, cost-effectiveness and breadth of application advantages over alternative IVDs.
Our report has been authored to evaluate the US diagnostic market potentials, and identify future growth opportunities. It provides extensive research and analysis on current market trends and future forecasts on all prominent diagnostic techniques including medical imaging and in vitro diagnostics.
The report also provides an insight into the market consolidation over the past few years, the competitive landscape of both the diagnostics and lab services market. The future analysis of the market scenario is likely to assist the intending clients to take informed and proactive business decisions in the evolving US diagnostic market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. EMERGING MARKET TRENDS AND DRIVERS
3.1 Diagnostics: Heading Towards Diversified Applications
3.2 Cancer Diagnostics: Key Focus Area for Industry Players
3.3 Patient Monitoring: Benefiting from Diagnostic Advancements
3.4 Improving Life Expectancy: Stimulating Diagnostic Market
3.5 Molecular Diagnostics: Future of Disease Diagnosis
3.6 Personalized Medicine: Revolutionizing Diagnostics
4. INDUSTRY OVERVIEW
4.1 Medical Imaging Equipments
4.1.1 Magnetic Resonance Imaging
4.1.2 Ultrasound
4.1.3 Computed Tomography (CT) Scanners
4.1.4 X-Ray Systems
4.2 IVD Products
4.2.1 Immunoassay
4.2.2 Clinical Chemistry
4.2.3 Blood Testing
4.2.4 Molecular Diagnostics
4.3 Segmentation by Indication
4.3.1 Diabetes
4.3.2 Cardiovascular
4.3.3 Cancer
4.3.4 HIV
5. CLINICAL LAB SERVICES MARKET
6. MARKET CONSOLIDATIONS
7. COMPETITIVE LANDSCAPE
7.1 By Diagnostic Products
7.1.1 Roche Holding Ltd.
7.1.2 Johnson & Johnson
7.1.3 BioMérieux S.A.
7.1.4 Siemens AG
7.1.5 Becton Dickinson
7.1.6 Abbott Laboratories
7.1.7 Beckman Coulter Inc.
7.1.8 Hologic Inc.
7.1.9 QIAGEN
7.1.10 Thermo Fisher Scientific Inc.
7.2 By Services
7.2.1 Quest Diagnostics Inc.
7.2.2 Laboratory Corporation of America Holdings
7.2.3 Genomic Health Inc.
2. RESEARCH METHODOLOGY
3. EMERGING MARKET TRENDS AND DRIVERS
3.1 Diagnostics: Heading Towards Diversified Applications
3.2 Cancer Diagnostics: Key Focus Area for Industry Players
3.3 Patient Monitoring: Benefiting from Diagnostic Advancements
3.4 Improving Life Expectancy: Stimulating Diagnostic Market
3.5 Molecular Diagnostics: Future of Disease Diagnosis
3.6 Personalized Medicine: Revolutionizing Diagnostics
4. INDUSTRY OVERVIEW
4.1 Medical Imaging Equipments
4.1.1 Magnetic Resonance Imaging
4.1.2 Ultrasound
4.1.3 Computed Tomography (CT) Scanners
4.1.4 X-Ray Systems
4.2 IVD Products
4.2.1 Immunoassay
4.2.2 Clinical Chemistry
4.2.3 Blood Testing
4.2.4 Molecular Diagnostics
4.3 Segmentation by Indication
4.3.1 Diabetes
4.3.2 Cardiovascular
4.3.3 Cancer
4.3.4 HIV
5. CLINICAL LAB SERVICES MARKET
6. MARKET CONSOLIDATIONS
7. COMPETITIVE LANDSCAPE
7.1 By Diagnostic Products
7.1.1 Roche Holding Ltd.
7.1.2 Johnson & Johnson
7.1.3 BioMérieux S.A.
7.1.4 Siemens AG
7.1.5 Becton Dickinson
7.1.6 Abbott Laboratories
7.1.7 Beckman Coulter Inc.
7.1.8 Hologic Inc.
7.1.9 QIAGEN
7.1.10 Thermo Fisher Scientific Inc.
7.2 By Services
7.2.1 Quest Diagnostics Inc.
7.2.2 Laboratory Corporation of America Holdings
7.2.3 Genomic Health Inc.
LIST OF FIGURES:
Figure 3-1: Patient Monitoring System Demand (Billion US$), 2014-2020
Figure 4-1: Medical Imaging Market Segmentation by Products (%), 2014
Figure 4-2: Medical Imaging Market Segmentation by Products (%), 2020
Figure 4-3: Medical Imaging Market (Billion US$), 2014-2020
Figure 4-4: Magnetic Resonance Imaging Market (Billion US$), 2014-2020
Figure 4-5: Ultrasound Imaging Market (Billion US$), 2014-2020
Figure 4-6: Computed Tomography (CT) Scanners Market (Billion US$), 2014-2020
Figure 4-7: X-Ray Systems Market (Billion US$), 2014-2020
Figure 4-8: IVD Products Market (Billion US$), 2014-2020
Figure 4-9: IVD Products Market by Clinical Segment (%), 2014
Figure 4-10: IVD Products Market by Clinical Segment (%), 2020
Figure 4-11: Immunoassay Diagnostics Market (Billion US$), 2014-2020
Figure 4-12: Clinical Chemistry Market (Billion US$), 2014-2020
Figure 4-13: Blood Testing Market (Billion US$), 2014-2020
Figure 4-14: Molecular Diagnostics Market (Billion US$), 2014-2020
Figure 4-15: Number of Diabetics in the US (Million), 2014 & 2030
Figure 4-16: Blood Glucose Monitoring Systems Market (Billion US$), 2014-2020
Figure 4-17: Cardiovascular Diagnostics Market (Billion US$), 2014-2020
Figure 4-18: Cancer Diagnostics Market (Billion US$), 2014-2020
Figure 5-1: Breakup of Clinical Lab Market by Services (%), 2014
Figure 5-2: Breakup of Outside Hospital Lab Services (%), 2014
Figure 5-3: Clinical Lab Services Market (Billion US$), 2014-2020
Figure 3-1: Patient Monitoring System Demand (Billion US$), 2014-2020
Figure 4-1: Medical Imaging Market Segmentation by Products (%), 2014
Figure 4-2: Medical Imaging Market Segmentation by Products (%), 2020
Figure 4-3: Medical Imaging Market (Billion US$), 2014-2020
Figure 4-4: Magnetic Resonance Imaging Market (Billion US$), 2014-2020
Figure 4-5: Ultrasound Imaging Market (Billion US$), 2014-2020
Figure 4-6: Computed Tomography (CT) Scanners Market (Billion US$), 2014-2020
Figure 4-7: X-Ray Systems Market (Billion US$), 2014-2020
Figure 4-8: IVD Products Market (Billion US$), 2014-2020
Figure 4-9: IVD Products Market by Clinical Segment (%), 2014
Figure 4-10: IVD Products Market by Clinical Segment (%), 2020
Figure 4-11: Immunoassay Diagnostics Market (Billion US$), 2014-2020
Figure 4-12: Clinical Chemistry Market (Billion US$), 2014-2020
Figure 4-13: Blood Testing Market (Billion US$), 2014-2020
Figure 4-14: Molecular Diagnostics Market (Billion US$), 2014-2020
Figure 4-15: Number of Diabetics in the US (Million), 2014 & 2030
Figure 4-16: Blood Glucose Monitoring Systems Market (Billion US$), 2014-2020
Figure 4-17: Cardiovascular Diagnostics Market (Billion US$), 2014-2020
Figure 4-18: Cancer Diagnostics Market (Billion US$), 2014-2020
Figure 5-1: Breakup of Clinical Lab Market by Services (%), 2014
Figure 5-2: Breakup of Outside Hospital Lab Services (%), 2014
Figure 5-3: Clinical Lab Services Market (Billion US$), 2014-2020
LIST OF TABLES:
Table 3-1: Life Expectancy and Prevalence of Diseases by Countries
Table 4-1: List of HIV Diagnostic Products
Table 6-1: Recent M&A in the US Diagnostics Market (2012 - 2015)
Table 7-1: Roche Holding Ltd. - Revenue by Business Segments (Million CHF), 2013 & 2014
Table 7-2: Roche Holding Ltd. - Strengths & Weaknesses
Table 7-3: Johnson & Johnson - Breakup of Medical Device Business (Million US$), 2013 & 2014
Table 7-4: Johnson & Johnson - Strengths & Weaknesses
Table 7-5: BioMerieux S.A. - Revenue by Business Segments (Million Euros), 2013 & 2014
Table 7-6: BioMérieux S.A. - Strengths & Weaknesses
Table 7-7: Siemens AG - Strengths & Weaknesses
Table 7-8: Becton Dickinson - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-9: Becton Dickinson - Strengths & Weaknesses
Table 7-10: Abbott Laboratories - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-11: Abbott Laboratories - Strengths & Weaknesses
Table 7-12: Beckman Coulter Inc. - Strengths & Weaknesses
Table 7-13: Hologic Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-14: Hologic Inc. - Strengths & Weaknesses
Table 7-15: QIAGEN - Strengths & Weaknesses
Table 7-16: Thermo Fisher Scientific Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-17: Thermo Fisher Scientific Inc. - Strengths & Weaknesses
Table 7-18: Quest Diagnostics Inc. - Strengths & Weaknesses
Table 7-19: Laboratory Corporation of America Holdings - Strengths & Weaknesses
Table 7-20: Genomic Health Inc. - Strengths & Weaknesses
Table 3-1: Life Expectancy and Prevalence of Diseases by Countries
Table 4-1: List of HIV Diagnostic Products
Table 6-1: Recent M&A in the US Diagnostics Market (2012 - 2015)
Table 7-1: Roche Holding Ltd. - Revenue by Business Segments (Million CHF), 2013 & 2014
Table 7-2: Roche Holding Ltd. - Strengths & Weaknesses
Table 7-3: Johnson & Johnson - Breakup of Medical Device Business (Million US$), 2013 & 2014
Table 7-4: Johnson & Johnson - Strengths & Weaknesses
Table 7-5: BioMerieux S.A. - Revenue by Business Segments (Million Euros), 2013 & 2014
Table 7-6: BioMérieux S.A. - Strengths & Weaknesses
Table 7-7: Siemens AG - Strengths & Weaknesses
Table 7-8: Becton Dickinson - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-9: Becton Dickinson - Strengths & Weaknesses
Table 7-10: Abbott Laboratories - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-11: Abbott Laboratories - Strengths & Weaknesses
Table 7-12: Beckman Coulter Inc. - Strengths & Weaknesses
Table 7-13: Hologic Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-14: Hologic Inc. - Strengths & Weaknesses
Table 7-15: QIAGEN - Strengths & Weaknesses
Table 7-16: Thermo Fisher Scientific Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
Table 7-17: Thermo Fisher Scientific Inc. - Strengths & Weaknesses
Table 7-18: Quest Diagnostics Inc. - Strengths & Weaknesses
Table 7-19: Laboratory Corporation of America Holdings - Strengths & Weaknesses
Table 7-20: Genomic Health Inc. - Strengths & Weaknesses
